HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CIR Nearly Finished Assessing Citrus Component Safety

This article was originally published in The Rose Sheet

Executive Summary

Three years after initiating safety reviews of citrus substances, the Cosmetic Ingredient Review Expert Panel is on the verge of wrapping its work in the area. At its Sept. 19-20 meeting in Washington, the expert panel issued final safety assessments for six ingredient groups in total.

You may also be interested in...



CIR Panel Plans For Lead Acetate Review At FDA’s Request

While FDA has gone on record as being leery of proposed legislation that would formalize its relationship with the Cosmetic Ingredient Review, the agency continues to leverage the industry-funded program’s expertise. At FDA’s request, the CIR Expert Panel will review progressive hair dye lead acetate in 2017.

Cosmetic Ingredient Review Report Status

Chart: Data compiled by "The Rose Sheet" from information in CIR reports.

CIR Panel Emphasizes GMPs In Final 'Safe As Used' Ingredient Reports

Hexamethylene diisocyanate polymers and keratin/keratin-derived ingredients are safe as currently used in the cosmetics sector, provided that good manufacturing practices are being employed, the Cosmetic Ingredient Review Expert Panel suggests. The group issued four final assessments, advanced a slew of tentative reports and finalized its 2017 review priorities at its June 6-7 meeting in Washington.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS108609

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel